Drug Trial Radar · NCT05033132
A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer
Last checked: Nov 20, 2026Latest source record: Mar 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Oct 1, 2021
Primary completion
Dec 30, 2024
Study completion Dec 30, 2024
Sponsor
- Lead sponsor
- Agenus Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Betta Pharmaceuticals Co., Ltd.
- First posted
- Sep 2, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center Phase II clinical trial to assess the efficacy, safety, and pharmacokinetics of Balstilimab (Treatment Arm 1 - monotherapy) or in combination with Zalifrelimab (Treatment Arm 2 - combination therapy) for treatment of patients with advanced cervical cancer who relapsed or progressed after receiving first-line platinum-based chemotherapy.
Conditions
- Cervical Cancer
Interventions
BalstilimabDrug
Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody
Balstilimab + ZalifrelimabDrug
An anti-PD-1 monoclonal antibody in combination with a cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) Of Balstilimab Monotherapy Per Independent Review Committee (IRC) Assessment Based Upon Response Evaluation Criteria In Solid Tumours (RECIST) 1.1Time frame: 36 months
Locations
43 sites in 1 country. Site status is shown where the registry gives one.
Betta Clinical Study Site 4
Bengbu, Anhui, China
Betta Clinical Study Site 2
Hefei, Anhui, China
Betta Clinical Study Site 3
Hefei, Anhui, China
Betta Clinical Study Site 27
Wuhu, Anhui, China
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, Beijing Municipality, China
Betta Clinical Study Site 25
Beijing, Beijing Municipality, China
Betta Clinical Study Site 42
Chongqing, Chongqing Municipality, China
Betta Clinical Study Site 9
Fuzhou, Fujian, China
Betta Clinical Study Site 22
Xiamen, Fujian, China
Betta Clinical Study Site 41
Lanzhou, Gansu, China
Betta Clinical Study Site 39
Lanzhou, Gansu, China
Betta Clinical Study Site 14
Huizhou, Guangdong, China
Betta Clinical Study Site 18
Meizhou, Guangdong, China
Betta Clinical Study Site 10
Zhanjiang, Guangdong, China
Betta Clinical Study Site 11
Nanning, Guangxi, China
Betta Clinical Study Site 5
Cangzhou, Hebei, China
Betta Clinical Study Site 40
Harbin, Heilongjiang, China
Betta Clinical Study Site 43
Wuhan, Hubei, China
Betta Clinical Study Site 28
Wuhan, Hubei, China
Betta Clinical Study Site 12
Wuhan, Hubei, China
Betta Clinical Study Site 29
Wuhan, Hubei, China
Betta Clinical Study Site 31
Xiangyang, Hubei, China
Betta Clinical Study Site 6
Changde, Hunan, China
Betta Clinical Study Site 36
Changsha, Hunan, China
Betta Clinical Study Site 35
Changsha, Hunan, China
Betta Clinical Study Site 13
Changsha, Hunan, China
Betta Clinical Study Site 21
Nanjing, Jiangsu, China
Betta Clinical Study Site 8
Nanjing, Jiangsu, China
Betta Clinical Study Site 38
Ganzhou, Jiangxi, China
Betta Clinical Study Site 19
Nanchang, Jiangxi, China
Betta Clinical Study Site 20
Nanchang, Jiangxi, China
Betta Clinical Study Site 24
Shangrao, Jiangxi, China
Betta Clinical Study Site 16
Changchun, Jilin, China
Betta Clinical Study Site 15
Changchun, Jilin, China
Betta Clinical Study Site 7
Dalian, Liaoning, China
Betta Clinical Study Site 34
Shenyang, Liaoning, China
Betta Clinical Study Site 17
Shenyang, Liaoning, China
Betta Clinical Study Site 30
Xi'an, Shaanxi, China
Betta Clinical Study Site 23
Taiyuan, Shanxi, China
Betta Clinical Study Site 26
Tianjin, Tianjin Municipality, China
Showing 40 of 43 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.